

IN THE CLAIMS:

Please amend claims 5 and 7 as follows:

In claim 5, line 2, please replace "portion" with --domain-- ✓

7¹ 7. (Three times amended) The isolated polypeptide as defined by claim 26, conjugated with a peptide having [an immune epitope] immunogenic properties in a human.

Please add the following claims:

--28. Isolated, glycosylated, secreted HER2 extracellular domain which terminates upstream of the transmembrane portion of the HER2 molecule.--

--29. The HER2 extracellular domain of claim 28 which has a molecular weight of about 103kD.--

--30. The HER2 extracellular domain of claim 28 which terminates at least about eight amino acid residues upstream of the transmembrane portion of the HER2 molecule.--

7² --31. The HER2 extracellular domain of claim 28 which is immunogenic in a human.--

--32. The HER2 extracellular domain of claim 31 which is conjugated with a peptide having immunogenic properties in the human.--

--33. A vaccine comprising the HER2 extracellular domain of claim 28 and an immune adjuvant.--

--34. The vaccine of claim 33 wherein the immune adjuvant is selected from the group consisting of alum, Bacillus calmette-Guerin (BCG), an adjuvant derived from BCG cell walls, Detox, Syntex-1, Corynebacterium parvum, interferon gamma, interleukin 1, interleukin 2 and interleukin 6.--

--35. The vaccine of claim 33 which provokes a humoral and cell-mediated response upon administration to a patient.--